Abstract – Overall
Approximately 40 million people worldwide are living with HIV/AIDS; however, a protective vaccine or
functional cure remain elusive despite four decades of intense research. HIV-1 evades the immune system
through its rapid structural evolution during infection and replication. The proposed Duke Center for HIV
Structural Biology will provide new insights into the dynamics of HIV-1 entry and fusion with the host
membrane, the Env-initiated immune activation of B-cell receptors, and the role of anti-Env antibodies in
blocking viral rebound. The Center will pursue structural studies that aim to 1) to develop a complete, time
resolved and atomically detailed mechanism of HIV-1 Env fusion; 2) to define BCR complex structures with
specificity of autologous (anAb) and broadly neutralizing antibodies (bnAb); and 3) to achieve an atomic level
understanding of antibody-mediated control of rebound from latent HIV-1 reservoirs. The ultimate goal of these
studies is to advance structural biology techniques and knowledge of HIV-1 Env structure-derived disease
mechanisms in HIV-1 infection and rebound. Additionally, through its Developmental Core, the Center will
provide resources and training opportunities for early career investigators and trainees who are pursuing
careers in the field of HIV-1 structural biology.
Public Health Relevance Statement
Narrative
Approximately 40 million people worldwide are living with HIV/AIDS; however, a protective vaccine or
functional cure remain elusive despite four decades of intense research. The proposed Duke Center for HIV
Structural Biology will provide new insights into the dynamics of HIV-1 entry and fusion with the host
membrane, the Env-initiated immune activation of B-cell receptors, and the role of anti-Env antibodies in
blocking viral rebound. The ultimate goal of these studies is to advance structural biology techniques and
knowledge of HIV-1 Env structure-derived disease mechanisms in HIV-1 infection and rebound.
National Institute of Allergy and Infectious Diseases
CFDA Code
855
DUNS Number
044387793
UEI
TP7EK8DZV6N5
Project Start Date
14-June-2022
Project End Date
31-March-2027
Budget Start Date
01-April-2024
Budget End Date
31-March-2025
Project Funding Information for 2024
Total Funding
$5,412,818
Direct Costs
$4,500,489
Indirect Costs
$1,729,296
Year
Funding IC
FY Total Cost by IC
2024
National Institute of Allergy and Infectious Diseases
$5,412,818
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5U54AI170752-03
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5U54AI170752-03
Patents
No Patents information available for 5U54AI170752-03
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5U54AI170752-03
Clinical Studies
No Clinical Studies information available for 5U54AI170752-03
News and More
Related News Releases
No news release information available for 5U54AI170752-03
History
No Historical information available for 5U54AI170752-03
Similar Projects
No Similar Projects information available for 5U54AI170752-03